Zacks Investment Research cut shares of Uniqure (NASDAQ:QURE) from a buy rating to a hold rating in a research note released on Wednesday.
According to Zacks, “UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company’s product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. “
A number of other brokerages also recently issued reports on QURE. HC Wainwright lifted their price target on shares of Uniqure from $42.00 to $48.00 and gave the stock a buy rating in a research note on Monday, September 24th. Cantor Fitzgerald set a $58.00 price target on shares of Uniqure and gave the stock a buy rating in a research note on Thursday, August 23rd. BidaskClub downgraded shares of Uniqure from a strong-buy rating to a buy rating in a research note on Friday, September 28th. Cowen reiterated a buy rating on shares of Uniqure in a research note on Monday, August 13th. Finally, B. Riley assumed coverage on shares of Uniqure in a research note on Wednesday, June 27th. They issued a buy rating and a $50.00 price target for the company. Three analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $44.90.
Uniqure (NASDAQ:QURE) last issued its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.04. Uniqure had a negative net margin of 677.98% and a negative return on equity of 72.12%. The company had revenue of $3.05 million during the quarter, compared to the consensus estimate of $3.37 million. On average, equities research analysts anticipate that Uniqure will post -2.44 EPS for the current fiscal year.
Several large investors have recently modified their holdings of QURE. California Public Employees Retirement System purchased a new stake in shares of Uniqure during the 1st quarter worth approximately $332,000. Jane Street Group LLC purchased a new stake in shares of Uniqure during the 1st quarter worth approximately $224,000. Ladenburg Thalmann Financial Services Inc. lifted its position in shares of Uniqure by 276.5% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,400 shares of the biotechnology company’s stock worth $150,000 after buying an additional 4,700 shares during the last quarter. Millennium Management LLC lifted its position in shares of Uniqure by 242.8% during the 1st quarter. Millennium Management LLC now owns 759,585 shares of the biotechnology company’s stock worth $17,850,000 after buying an additional 538,031 shares during the last quarter. Finally, Financial Gravity Wealth Inc. purchased a new stake in shares of Uniqure during the 1st quarter worth approximately $177,000. Institutional investors and hedge funds own 59.13% of the company’s stock.
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.
Featured Story: How much money do you need to begin day trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.